Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Døgnkursus 2009 - Ny Spildevandsforskning
Upcoming SlideShare
Loading in …5
×

Døgnkursus 2009 - Ny Spildevandsforskning

266 views

Published on

Presentation for the Spildevandsteknisk Forening (Wastewater technology association (of Denmark))

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
266
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • 21-04-11 Identification of pharmaceuticals of environmental concern MistraPharma will contribute to identifying the active pharmaceutical ingredients on the Swedish market most likely to cause adverse effects in the aquatic environment. The programme will also generate data on which molecular structure elements that are important for biodegradability of pharmaceutical compounds. Recommendations to improve wastewater treatment technologies   MistraPharma will identify and develop wastewater treatment technologies that will help improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any recommendations to improve waste water treatment will be based on an integrated analysis taking into account what is environmentally motivated, technically feasible and economically realistic.   Improved risk identification strategies   MistraPharma will develop new tools for detecting environmental effects of human pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using explorative methods covering a broad range of biological interactions. Based on these methods MistraPharma will propose new approaches to ecotoxicological testing of  pharmaceuticals. Stakeholder communication   MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry, national, regional and local authorities and health care, are actively informed about and given access to the new knowledge and expertise that will enable them to limit the effects of human pharmaceuticals in the aquatic environment.
  • 21-04-11 Identification of pharmaceuticals of environmental concern MistraPharma will contribute to identifying the active pharmaceutical ingredients on the Swedish market most likely to cause adverse effects in the aquatic environment. The programme will also generate data on which molecular structure elements that are important for biodegradability of pharmaceutical compounds. Recommendations to improve wastewater treatment technologies   MistraPharma will identify and develop wastewater treatment technologies that will help improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any recommendations to improve waste water treatment will be based on an integrated analysis taking into account what is environmentally motivated, technically feasible and economically realistic.   Improved risk identification strategies   MistraPharma will develop new tools for detecting environmental effects of human pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using explorative methods covering a broad range of biological interactions. Based on these methods MistraPharma will propose new approaches to ecotoxicological testing of  pharmaceuticals. Stakeholder communication   MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry, national, regional and local authorities and health care, are actively informed about and given access to the new knowledge and expertise that will enable them to limit the effects of human pharmaceuticals in the aquatic environment.
  • 21-04-11 Identification of pharmaceuticals of environmental concern MistraPharma will contribute to identifying the active pharmaceutical ingredients on the Swedish market most likely to cause adverse effects in the aquatic environment. The programme will also generate data on which molecular structure elements that are important for biodegradability of pharmaceutical compounds. Recommendations to improve wastewater treatment technologies   MistraPharma will identify and develop wastewater treatment technologies that will help improve the elimination of high-risk pharmaceuticals from waste water treatment plants. Any recommendations to improve waste water treatment will be based on an integrated analysis taking into account what is environmentally motivated, technically feasible and economically realistic.   Improved risk identification strategies   MistraPharma will develop new tools for detecting environmental effects of human pharmaceuticals based on the compounds´ expected pharmacological mechanisms or using explorative methods covering a broad range of biological interactions. Based on these methods MistraPharma will propose new approaches to ecotoxicological testing of  pharmaceuticals. Stakeholder communication   MistraPharma will ensure that the stakeholders, such as the pharmaceutical industry, national, regional and local authorities and health care, are actively informed about and given access to the new knowledge and expertise that will enable them to limit the effects of human pharmaceuticals in the aquatic environment.
  • 21-04-11
  • 21-04-11
  • EP08163303 Use of clorine dioxide for removal of estrogenic substances in wastewater .
  • 21-04-11
  • 21-04-11
  • ×